Drug interactions
Glimepiride-pioglitazone + Pacritinib
Severity: Minor
Glimepiride-pioglitazone and Pacritinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pioglitazone is a weak CYP3A4 inducer and pacritinib is a CYP3A4 substrate, so pacritinib exposure could fall modestly. Clinical relevance is uncertain.
What this interaction means in plain words
Glimepiride-pioglitazone and Pacritinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Glimepiride-pioglitazone belongs to Endocrine; Pacritinib belongs to Oncology.
Why it happens
Weak CYP3A4 induction by pioglitazone may increase pacritinib metabolism.
What to do
No routine adjustment is needed. Monitor pacritinib response, including spleen and symptom control.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Glimepiride-pioglitazone and Pacritinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Glimepiride-pioglitazone
Other interactions of Pacritinib
- Clarithromycin + Pacritinib Contraindicated
- Ketoconazole + Pacritinib Contraindicated
- Pacritinib + Posaconazole Contraindicated
- Pacritinib + Voriconazole Contraindicated
- Amiodarone + Pacritinib Major
- Carbamazepine + Pacritinib Major
Frequently asked questions
Can I take Glimepiride-pioglitazone with Pacritinib?
MediHelp rates the interaction as minor. Glimepiride-pioglitazone and Pacritinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Pioglitazone is a weak CYP3A4 inducer and pacritinib is a CYP3A4 substrate, so pacritinib exposure could fall modestly. Clinical relevance is uncertain.
How serious is the interaction between Glimepiride-pioglitazone and Pacritinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine adjustment is needed. Monitor pacritinib response, including spleen and symptom control.
What other medicines interact with Glimepiride-pioglitazone?
MediHelp also lists interactions of Glimepiride-pioglitazone with, for example, Fluconazole, Gemfibrozil, Insulin aspart. The full list is on the Glimepiride-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
